Updated data from Covaxin phase 3 trial shows 78% efficacy
The Hindu
The efficacy against severe COVID-19 disease was 100%, Bharat Biotech claimed, but that against protecting from asymptomatic COVID-19 infection was 70%
The efficacy of Covaxin has dropped a tad lower - 78% - than the 81% reported in March. On Wednesday, Bharat Biotech, via a press release, announced results from an interim analysis of its phase 3 trial. The efficacy against severe COVID-19 disease was 100%, the company claimed, but that against protecting from asymptomatic COVID-19 infection was 70%. The analysis was on a data set of 127 Covid positive volunteers. The safety and efficacy results from the final analysis would be available in June, and the final report will be submitted to a peer-reviewed publication. “Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of COVAXIN,” Bharat Biotech said in a statement.More Related News